Pfizer Inc ((PFE)), Biontech Se Sponsored Adr ((BNTX)), Biontech SE (($CC:BNTX.CUR)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Pfizer Inc. and BioNTech SE are conducting a clinical study titled ‘A Phase 1/2 Randomized, Observer-Blind Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Modified RNA Vaccine Against Varicella Zoster Virus in Healthy Individuals.’ This study aims to assess the safety and immune response of a new modified RNA vaccine for shingles in adults aged 50 to 85, which could offer a significant advancement in preventing this common viral infection.
The intervention being tested is the Varicella Zoster Virus modRNA (VZV modRNA) vaccine, administered intramuscularly. This vaccine is designed to trigger an immune response to protect against shingles, with various formulations and dosing schedules being explored.
The study is interventional, with a randomized allocation and a sequential intervention model. It employs a quadruple masking technique, meaning participants, care providers, investigators, and outcomes assessors are blinded to the treatment groups. The primary purpose is prevention.
The study began on January 25, 2023, and is currently active but not recruiting. The primary completion and estimated completion dates are not specified, but the last update was submitted on August 5, 2025. These dates are crucial for tracking the study’s progress and anticipating results.
This clinical study update could positively impact Pfizer and BioNTech’s stock performance by showcasing their ongoing innovation in vaccine development. As the study progresses, investor sentiment may be influenced by the potential for a new shingles vaccine to capture market share, especially in comparison to existing options like Shingrix.
The study is ongoing, and further details are available on the ClinicalTrials portal.